Immune checkpoint inhibitors (ICIs) have gained increasing attention in cervical cancer treatment due to their potential to restore T cell-mediated antitumor immunity, among which CTLA-4 and PD-1/PD-L1 are the most extensively studied regulators. This evidence concerns the gene PDCD1 and cervical carcinoma.